Key result
PRECAD trial tests aggressive multi-risk-factor control to prevent early atherosclerosis progression in young adults.
Why the study?
Does aggressive control of cardiovascular risk factors prevent the onset or progression of atherosclerosis in young adults aged 20 to 39 years without known cardiovascular disease?
RCT
randomized
Does aggressive control of cardiovascular risk factors prevent the onset or progression of atherosclerosis in young adults aged 20 to 39 years without known cardiovascular disease?
Answers are grounded in this paper and cite their sources.
The PRECAD trial will evaluate whether aggressive control of cardiovascular risk factors prevents the onset or progression of subclinical atherosclerosis in healthy young adults.
There is growing evidence that the atherosclerotic process that leads to symptomatic cardiovascular disease (CVD) starts at an early age. In young adults, exposure to low-density lipoprotein-cholesterol and other cardiovascular risk factor (CVRF) mediators, even at levels considered within normal limits, increases the prevalence of subclinical atherosclerosis and is associated with greater risk of cardiovascular events later in life. The optimal CVRF targets to prevent CVD in asymptomatic young individuals (<40 years) are unknown. The randomized controlled PRECAD (Prevent Coronary Artery Disease) trial has been developed to assess the potential benefit of an aggressive control of CVRF in otherwise healthy young adults. The hypothesis of PRECAD is that in subjects aged 20 to 39 years without known CVD, maintaining low-density lipoprotein-cholesterol <70 mg/dL and strict control of blood pressure and glucose will prevent the onset of atherosclerosis and/or its progression. The primary endpoint will be the change in total atherosclerosis burden, a surrogate for CVD.
No takes yet. Share an insight, caveat, or question.
Devesa et al. (2023) conducted an RCT in Subclinical atherosclerosis. Aggressive control of cardiovascular risk factors (maintaining LDL-C <70 mg/dL and strict control of blood pressure and glucose) was evaluated on Change in total atherosclerosis burden. The PRECAD trial is designed to assess whether maintaining LDL-C </dL and strict control of blood pressure and glucose prevents atherosclerosis progression in adults aged 20 to 39 years.
Synapse has enriched 10 related papers. Consider them for comparative context: